Evidence map›Paper›PMID 38418669›Full record

ReviewHandbook of experimental pharmacology2025

Natural Products for the Management of Asthma and COPD.

Wupeng Liao, Quy T N Tran, Hong Yong Peh, Christabel Clare M Y Chan, W S Fred Wong

Abstract readReview
PubMed Publisher
In one paragraph

Review in Handbook of experimental pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Review
  4. Article
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Wupeng LiaoDepartment of Pharmacology, Yong Loo Lin School of Medicine, National University Health System, Singapore, Singapore.
Quy T N TranDepartment of Pharmacology, Yong Loo Lin School of Medicine, National University Health System, Singapore, Singapore.
Hong Yong PehDepartment of Pharmacology, Yong Loo Lin School of Medicine, National University Health System, Singapore, Singapore.
Christabel Clare M Y ChanDepartment of Pharmacology, Yong Loo Lin School of Medicine, National University Health System, Singapore, Singapore.
W S Fred WongDepartment of Pharmacology, Yong Loo Lin School of Medicine, National University Health System, Singapore, Singapore. phcwongf@nus.edu.sg.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Chronic airway inflammatory diseases like asthma, chronic obstructive pulmonary disease (COPD), and their associated exacerbations cause significant socioeconomic burden. There are still major obstacles to effective therapy for controlling severe asthma and COPD progression. Advances in understanding the pathogenesis of the two diseases at the cellular and molecular levels are essential for the development of novel therapies. In recent years, significant efforts have been made to identify natural products as potential drug leads for treatment of human diseases and to investigate their efficacy, safety, and underlying mechanisms of action. Many major active components from various natural products have been extracted, isolated, and evaluated for their pharmacological efficacy and safety. For the treatment of asthma and COPD, many promising natural products have been discovered and extensively investigated. In this chapter, we will review a range of natural compounds from different chemical classes, including terpenes, polyphenols, alkaloids, fatty acids, polyketides, and vitamin E, that have been demonstrated effective against asthma and/or COPD and their exacerbations in preclinical models and clinical trials. We will also elaborate in detail their underlying mechanisms of action unraveled by these studies and discuss new opportunities and potential challenges for these natural products in managing asthma and COPD.

Indexed as

Anti-Asthmatic AgentsAsthmaBiological ProductsPulmonary Disease, Chronic ObstructiveAnimalsHumansAnti-Asthmatic AgentsBiological ProductsAlkaloidAsthmaCOPDFatty acidPolyketidePolyphenolTerpeneVitamin E

Identifiers

PMID38418669

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.